OTUB2-IN-1, a specific inhibitor of OTUB2 (KD: ~12 μM), reduces PD-L1 protein expression in tumor cells and inhibits tumor growth by promoting robust intra-tumor infiltration of cytotoxic T lymphocytes (CTL) .

N-Acetylcysteine amide is a cell membranes and blood brain barrier permeant thiol antioxidant and neuroprotective agent, reduces ROS production.

Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively.

BP Lipid 222 BP Lipid 222 is an butanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315 (BP-25498). The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 211 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. Both ester bonds are located at C10 position relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

1LNP Lipid-7 (Compound 7013) is a lipid. LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP) and for drug delivery.

BP Lipid 309 is an ionizable lipid analogue of ALC-0315 featuring a tertiary amine head, a central tertiary amine, and two identical esters linking to nonpolar tails. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 307 is a multi-ionizable amino-lipid featuring a dimethylamine headgroup, a central tertiary amine, and two identical ester branches linking to saturated C17 tails. This compound may be employed in the development of lipid nanoparticles for drug delivery.

BP Lipid 318 is a lipid analog comprised of three unsaturated fatty acid tails and an ionizable dimethylamino butanoate head group. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA delivery.

BP Lipid 316 is an ionizable lipid analogue of DLin-MC3-DMA featuring a 4-(dimethylamino)butanoate head, two linoleic acid tails, and one primary alcohol. The alcohol may be used to further derivatize this compound. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 317 is an amino lipid featuring a dimethylamine headgroup connected to two oleic esters and a hydroxy group which may be used for further derivatization. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 320 is an ionizable amino lipid comprised of three oleic fatty acid tails and a novel pyrrolidine head group four carbon atoms in length. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA delivery.

BP Lipid 315 is a cationic ionizable lipid ALC-0315 analogue featuring a Boc-protected primary amine, a central tertiary amine, and two ester tails located at the C8 position relative to the amine. One of these esters features a symmetrical branched C17 tail, while the other is an asymmetric C11 tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 319 is a multi-ionizable amino lipid analogue of ALC-0315 featuring a propylamino headgroup and two acyl tails, one being a branched symmetrical C17 and the other being an asymmnetrical C11 chain. Ionizable lipids such as this may be applied in the development of lipid nanoparticles.

BP Lipid 312 is a cationic ionizable lipid analogue of LP01, with the substitution of a polyunsaturated tail for a monounsaturated equivalent. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 311 is a branched amino lipid featuring a dimethylamino headgroup, esters of a palmitoleic acid group and an aliphatic acetal. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.